Global Amrinon (CAS 60719-84-8) Market Size By Type (50mg/Vail, 100mg/Vail), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Amrinon (CAS 60719-84-8) Market was valued at USD 312 million in 2023 and is projected to reach USD 478 million by 2031, growing at a CAGR of 5.5% during the forecast period from 2023 to 2031. Amrinon, a phosphodiesterase III inhibitor, is widely used in the treatment of congestive heart failure due to its inotropic and vasodilatory properties. The increasing incidence of cardiovascular diseases, the aging global population, and the growing need for effective acute heart failure therapies are key contributors to the market's expansion.

Drivers:

1. Rising Prevalence of Cardiovascular Disorders:

The global increase in cardiovascular diseases—particularly congestive heart failure—is a major factor driving the demand for Amrinon. As lifestyle-related illnesses grow more prevalent, the need for effective cardiac drugs has surged.

2. Growth in Geriatric Population:

Elderly individuals are at higher risk of heart conditions, making them a significant consumer base for Amrinon. The expanding global geriatric demographic is consequently boosting market demand.

3. Ongoing Clinical Research and Drug Development:

Investments in R&D, including studies exploring novel delivery mechanisms and combination therapies with Amrinon, are broadening its therapeutic scope and enhancing its commercial appeal.

Restraints:

1. Risk of Adverse Effects:

Amrinon is associated with side effects such as thrombocytopenia and arrhythmias, which can limit its adoption. The availability of newer alternatives with improved safety profiles may further restrain market growth.

2. Regulatory Challenges:

Stringent drug approval regulations and periodic re-evaluations of cardiovascular drug efficacy and safety can delay product launches and restrict market expansion in certain regions.

Opportunity:

1. Emerging Market Penetration:

Rapidly developing healthcare infrastructure in Asia-Pacific and Latin America offers lucrative opportunities for the expansion of Amrinon, especially in countries prioritizing cardiac health.

2. Potential for Expanded Indications:

Ongoing clinical trials exploring the use of Amrinon beyond acute heart failure, such as in specific types of cardiomyopathies, could open new therapeutic avenues and commercial opportunities.

Market by System Type Insights:

Based on product form, the injectable Amrinon segment accounted for the largest market share in 2023. Intravenous administration remains the preferred route in acute care settings, due to its rapid onset of action. This segment is expected to maintain its lead, driven by its use in emergency departments and intensive care units globally.

Market by End-Use Insights:

In 2023, the hospital segment dominated the market, holding more than 60% of total revenue. Hospitals are the primary centers for administering Amrinon in acute care and cardiac emergencies. Additionally, increasing cardiac admissions and the rise of specialty cardiac centers reinforce hospital-centric demand.

Market by Regional Insights:

North America led the global market in 2023, supported by high healthcare expenditure, strong awareness of cardiovascular treatment, and robust clinical infrastructure. However, Asia-Pacific is projected to witness the fastest growth during the forecast period, attributed to expanding healthcare services, growing aging populations, and increasing cardiovascular disease prevalence in countries like India and China.

Competitive Scenario:

Key players in the Global Amrinon Market include Teva Pharmaceuticals, Mylan N.V., Hikma Pharmaceuticals, Pfizer Inc., and Aurobindo Pharma. These companies are focusing on regulatory approvals, portfolio diversification, and regional expansion. For example:

In 2024, Teva Pharmaceuticals initiated a regional distribution partnership in Southeast Asia to improve availability of Amrinon injectable formulations.

In 2023, Mylan received US FDA approval for a generic version of Amrinon for hospital use.

Scope of Work – Global Amrinon (CAS 60719-84-8) Market

Key Market Developments:

2024: Teva Pharmaceuticals expanded its injectable cardiovascular drug line with improved packaging and stability features, targeting emergency room usage.

2023: Aurobindo Pharma began clinical trials to evaluate Amrinon in combination with beta-blockers for enhanced heart failure management.

2023: Pfizer released updated clinical safety data confirming low thrombocytopenia incidence in controlled use of Amrinon, boosting physician confidence.

FAQs:

1. What is the current market size of the Global Amrinon (CAS 60719-84-8) Market?

The market was valued at USD 312 million in 2023.

2. What is the major growth driver of the Global Amrinon Market?

The primary growth driver is the rising prevalence of cardiovascular diseases, particularly acute and chronic heart failure.

3. Which is the largest region during the forecast period in the Global Amrinon Market?

North America is expected to retain the largest market share through 2031.

4. Which segment accounted for the largest market share in the Global Amrinon Market?

The injectable segment held the largest market share in 2023, driven by its critical role in acute cardiac care.

5. Who are the key market players in the Global Amrinon Market?

Key players include Teva Pharmaceuticals, Mylan N.V., Hikma Pharmaceuticals, Pfizer Inc., and Aurobindo Pharma.